Pharmacokinetic-pharmacodynamic Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-induced Arthritis

The purpose of this study was to develop a pharmacokinetic-pharmacodynamic disease progression (PK/PD/DIS) model to characterize the effect of etanercept in collagen-induced arthritis (CIA) rats on rheumatoid arthritis (RA) progression.
The CIA rats received either 5 mg/kg intravenous (IV), 1 mg/kg IV, or 5 mg/kg subcutaneous (SC) etanercept at day 21 post-disease induction. Effect on disease progression was measured by paw swelling.



Powered by GlobalLink OneLink Software